You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Novartis reports ‘clinically relevant’ survival data for Lutathera

Novartis has reported findings of a final analysis of data from the Phase III Netter trial, showing that its radioligand therapy Lutathera (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) extended overall survival in patients with midgut neuroendocrine tumours.